Establishment Labs’ second-quarter revenue rose 31.7% year over year to $67.5 million, while adjusted EBITDA turned positive at $3.7 million from an $8.5 million loss. It raised 2026 revenue guidance to $269 million-$271 million despite an $11.7 million net loss.
Gross margin was 70.6%, up from 68.8% a year earlier; U.S. sales climbed 26% sequentially to $24.7 million. Operating expenses rose to $52.0 million from $49.4 million, including $2.2 million in one-time debt-refinancing and restructuring charges. The company had $71.2 million in cash on its balance sheet on June 30, 2026, and reported a $4.3 million operating loss.
The minimally invasive Preservé and Mia platforms contributed $12.1 million of quarterly revenue; the article says core growth still relies on established Motiva implants. At a September 21 symposium in Istanbul, the company presented research on breast-tissue preservation and announced new sizes for Preservé and Mia. The article reports short interest at 18.44% of the float and 33 hedge funds holding shares, down from 36 the prior quarter.
